Share this article on:

New cardiovascular biomarkers in animal models: what can be expected in the coming years?

Oyama, Mark A.

Cardiovascular Endocrinology: March 2014 - Volume 3 - Issue 1 - p 27–31
doi: 10.1097/XCE.0000000000000026
Cardiovascular Biomarkers in Animal Models – A Bridge to Human Disease Edited by Jens Peter Goetze and Lisbeth Høier Olsen: Reviews

Animal models of disease provide the basis for important scientific inquiry of proof of concept, drug safety and efficacy, and exploration of the mechanistic and pathophysiological aspects of disease. Animals with either induced cardiac disease or spontaneously occurring cardiac disease are test beds for new cardiovascular therapies or interventions. Biomarkers in animal models can help characterize disease, stratify risk of morbidity and mortality, and serve as surrogate endpoints. Biomarkers identify important similarities and differences between the animal model and the human condition. The future of biomarkers and animal models includes cross-organ investigation using multiorgan multimarker panels. Industry will use animal models and biomarkers to help shorten the time from drug discovery to market. Biomarker development has outpaced their acceptance in clinical use and carefully designed clinical studies are needed to achieve their maximum potential.

Department of Clinical Studies, Philadelphia School of Veterinary Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA

Correspondence to Mark A. Oyama, DVM, Department of Clinical Studies Philadelphia, School of Veterinary Medicine, University of Pennsylvania, 3900 Delancey St, Philadelphia, PA 19104, USA Tel: +1 215 898 8889; fax: +1 215 573 6232; e-mail:

Received September 14, 2013

Accepted January 7, 2014

© 2014Wolters Kluwer Health Lippincott Williams Wilkins